Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
The effect of the drug can be improved if the dosage is increased or given over shorter time intervals, but efficacy is not restored if the treatment is halted temporarily. 1 In the literature both words are used synonymously, for example in relation to anti-TNF-α biopharmaceuticals (infliximab) in...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2012-01, Vol.96 (1), p.1-2 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | British journal of ophthalmology |
| container_volume | 96 |
| creator | Binder, Susanne |
| description | The effect of the drug can be improved if the dosage is increased or given over shorter time intervals, but efficacy is not restored if the treatment is halted temporarily. 1 In the literature both words are used synonymously, for example in relation to anti-TNF-α biopharmaceuticals (infliximab) in chronic inflammatory diseases (including rheumatoid arthritis) where immunogenicity is suspected. 2 In diabetes research where rapid tachyphylaxis at the level of gastric nervous activation was described 3 and during treatment with salmeterol (a bronchodilator for chronic obstructive pulmonary disease), β2-receptor down-regulation was assumed to be a causative factor. 4 Furthermore, tachyphylaxis is known to occur with chronic aerosol use in patients with asthma, 5 and with drugs used for analgesia and anaesthesia. 6 In the ophthalmic literature, tachyphylaxis/tolerance is reported with the use of selective α-2 receptor agonists (brimonidine) due to up-regulation of α-2 receptors because the basal norepinephrine level in the synaptic junctions is chronically depressed. 7 The worldwide use of intravitreal application of anti-vascular growth factor (a-VEGF) in patients with neovascular age-related macular degeneration (AMD) and the realisation that regular applications over long periods of time are necessary to maintain vision in these eyes, has revealed the problem of tolerance/tachyphylaxy. |
| doi_str_mv | 10.1136/bjophthalmol-2011-301236 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_911931935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4012522901</sourcerecordid><originalsourceid>FETCH-LOGICAL-b490t-df307dfc8cf9a9747a406c8cc68245f3615e9544c1b534b121bfd2210c7596a03</originalsourceid><addsrcrecordid>eNqNkE1r3DAQQEVJaLbb_oVg6CEnpxrLkqxeStkmaWBJ2tKmRyFrZeyNvyppQ_zvO4uTpfQUGBAz82Y0PEISoOcATHwot8NYx9q03dCmGQVIGYWMiVdkAbkosCTVEVlQSmUKIOCEvAlhi2kmQL4mJ1kGXAqWLcj39RBCMlSJd8bG5qGJU9L0GNEbTLDaJqaPTXp3cXWZxNp5M04fk2hsPY311JrHBsd9EocWW711n96S48q0wb17epfk1-XFz9XXdH17db36vE7LXNGYbipG5aayha2UUTKXJqcCMyuKLOcVE8Cd4nluoeQsLyGDstrg3dRKroShbEnO5r2jH_7sXIi6a4J1bWt6N-yCVgCKYXAk3_9Hboed7_E4DVIWCo1xhVQxU9ajEu8qPfqmM37SQPXeuv7Xut5b17N1HD19-mBXdm5zGHzWjEA6A02I7vHQN_5eC8kk1zd3K01_UCF-f_mm9wvZzJfd9uVn_AVhyKCR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778946859</pqid></control><display><type>article</type><title>Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Binder, Susanne</creator><creatorcontrib>Binder, Susanne</creatorcontrib><description>The effect of the drug can be improved if the dosage is increased or given over shorter time intervals, but efficacy is not restored if the treatment is halted temporarily. 1 In the literature both words are used synonymously, for example in relation to anti-TNF-α biopharmaceuticals (infliximab) in chronic inflammatory diseases (including rheumatoid arthritis) where immunogenicity is suspected. 2 In diabetes research where rapid tachyphylaxis at the level of gastric nervous activation was described 3 and during treatment with salmeterol (a bronchodilator for chronic obstructive pulmonary disease), β2-receptor down-regulation was assumed to be a causative factor. 4 Furthermore, tachyphylaxis is known to occur with chronic aerosol use in patients with asthma, 5 and with drugs used for analgesia and anaesthesia. 6 In the ophthalmic literature, tachyphylaxis/tolerance is reported with the use of selective α-2 receptor agonists (brimonidine) due to up-regulation of α-2 receptors because the basal norepinephrine level in the synaptic junctions is chronically depressed. 7 The worldwide use of intravitreal application of anti-vascular growth factor (a-VEGF) in patients with neovascular age-related macular degeneration (AMD) and the realisation that regular applications over long periods of time are necessary to maintain vision in these eyes, has revealed the problem of tolerance/tachyphylaxy.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2011-301236</identifier><identifier>PMID: 22157632</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - therapeutic use ; Bevacizumab ; Choroidal Neovascularization - drug therapy ; Degeneration ; Drug dosages ; Female ; Humans ; Immunoglobulins ; Macular degeneration ; Macular Degeneration - drug therapy ; Male ; neovascularisation ; Ranibizumab ; Signal transduction ; Substance abuse treatment ; Tachyphylaxis</subject><ispartof>British journal of ophthalmology, 2012-01, Vol.96 (1), p.1-2</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b490t-df307dfc8cf9a9747a406c8cc68245f3615e9544c1b534b121bfd2210c7596a03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bjo.bmj.com/content/96/1/1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bjo.bmj.com/content/96/1/1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22157632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Binder, Susanne</creatorcontrib><title>Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>The effect of the drug can be improved if the dosage is increased or given over shorter time intervals, but efficacy is not restored if the treatment is halted temporarily. 1 In the literature both words are used synonymously, for example in relation to anti-TNF-α biopharmaceuticals (infliximab) in chronic inflammatory diseases (including rheumatoid arthritis) where immunogenicity is suspected. 2 In diabetes research where rapid tachyphylaxis at the level of gastric nervous activation was described 3 and during treatment with salmeterol (a bronchodilator for chronic obstructive pulmonary disease), β2-receptor down-regulation was assumed to be a causative factor. 4 Furthermore, tachyphylaxis is known to occur with chronic aerosol use in patients with asthma, 5 and with drugs used for analgesia and anaesthesia. 6 In the ophthalmic literature, tachyphylaxis/tolerance is reported with the use of selective α-2 receptor agonists (brimonidine) due to up-regulation of α-2 receptors because the basal norepinephrine level in the synaptic junctions is chronically depressed. 7 The worldwide use of intravitreal application of anti-vascular growth factor (a-VEGF) in patients with neovascular age-related macular degeneration (AMD) and the realisation that regular applications over long periods of time are necessary to maintain vision in these eyes, has revealed the problem of tolerance/tachyphylaxy.</description><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Bevacizumab</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Degeneration</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Male</subject><subject>neovascularisation</subject><subject>Ranibizumab</subject><subject>Signal transduction</subject><subject>Substance abuse treatment</subject><subject>Tachyphylaxis</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkE1r3DAQQEVJaLbb_oVg6CEnpxrLkqxeStkmaWBJ2tKmRyFrZeyNvyppQ_zvO4uTpfQUGBAz82Y0PEISoOcATHwot8NYx9q03dCmGQVIGYWMiVdkAbkosCTVEVlQSmUKIOCEvAlhi2kmQL4mJ1kGXAqWLcj39RBCMlSJd8bG5qGJU9L0GNEbTLDaJqaPTXp3cXWZxNp5M04fk2hsPY311JrHBsd9EocWW711n96S48q0wb17epfk1-XFz9XXdH17db36vE7LXNGYbipG5aayha2UUTKXJqcCMyuKLOcVE8Cd4nluoeQsLyGDstrg3dRKroShbEnO5r2jH_7sXIi6a4J1bWt6N-yCVgCKYXAk3_9Hboed7_E4DVIWCo1xhVQxU9ajEu8qPfqmM37SQPXeuv7Xut5b17N1HD19-mBXdm5zGHzWjEA6A02I7vHQN_5eC8kk1zd3K01_UCF-f_mm9wvZzJfd9uVn_AVhyKCR</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Binder, Susanne</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?</title><author>Binder, Susanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b490t-df307dfc8cf9a9747a406c8cc68245f3615e9544c1b534b121bfd2210c7596a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Bevacizumab</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Degeneration</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Male</topic><topic>neovascularisation</topic><topic>Ranibizumab</topic><topic>Signal transduction</topic><topic>Substance abuse treatment</topic><topic>Tachyphylaxis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Binder, Susanne</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Binder, Susanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>96</volume><issue>1</issue><spage>1</spage><epage>2</epage><pages>1-2</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>The effect of the drug can be improved if the dosage is increased or given over shorter time intervals, but efficacy is not restored if the treatment is halted temporarily. 1 In the literature both words are used synonymously, for example in relation to anti-TNF-α biopharmaceuticals (infliximab) in chronic inflammatory diseases (including rheumatoid arthritis) where immunogenicity is suspected. 2 In diabetes research where rapid tachyphylaxis at the level of gastric nervous activation was described 3 and during treatment with salmeterol (a bronchodilator for chronic obstructive pulmonary disease), β2-receptor down-regulation was assumed to be a causative factor. 4 Furthermore, tachyphylaxis is known to occur with chronic aerosol use in patients with asthma, 5 and with drugs used for analgesia and anaesthesia. 6 In the ophthalmic literature, tachyphylaxis/tolerance is reported with the use of selective α-2 receptor agonists (brimonidine) due to up-regulation of α-2 receptors because the basal norepinephrine level in the synaptic junctions is chronically depressed. 7 The worldwide use of intravitreal application of anti-vascular growth factor (a-VEGF) in patients with neovascular age-related macular degeneration (AMD) and the realisation that regular applications over long periods of time are necessary to maintain vision in these eyes, has revealed the problem of tolerance/tachyphylaxy.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>22157632</pmid><doi>10.1136/bjophthalmol-2011-301236</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2012-01, Vol.96 (1), p.1-2 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_911931935 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Choroidal Neovascularization - drug therapy Degeneration Drug dosages Female Humans Immunoglobulins Macular degeneration Macular Degeneration - drug therapy Male neovascularisation Ranibizumab Signal transduction Substance abuse treatment Tachyphylaxis |
| title | Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20reactivity%20in%20intravitreal%20anti-VEGF%20therapy:%20tachyphylaxis%20or%20tolerance?&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Binder,%20Susanne&rft.date=2012-01-01&rft.volume=96&rft.issue=1&rft.spage=1&rft.epage=2&rft.pages=1-2&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjophthalmol-2011-301236&rft_dat=%3Cproquest_cross%3E4012522901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778946859&rft_id=info:pmid/22157632&rfr_iscdi=true |